Suppliers and packagers for generic pharmaceutical drug: DEUCRAVACITINIB

DEUCRAVACITINIB

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958	NDA	E.R. Squibb & Sons, L.L.C.	0003-0895-11	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0003-0895-11)	2022-09-09
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958	NDA	E.R. Squibb & Sons, L.L.C.	0003-0895-91	30 TABLET, FILM COATED in 1 BLISTER PACK (0003-0895-91)	2022-09-09

Suppliers for the Pharmaceutical Drug: DEUCRAVACITINIB

Last updated: January 29, 2026

Executive Summary

Deucravacitinib (INN), marketed under the brand name Sotyktu (by AbbVie), is a selective TYK2 inhibitor approved for the treatment of moderate to severe plaque psoriasis. As of 2023, its supply chain comprises multiple suppliers involved in active pharmaceutical ingredient (API) manufacturing, formulation, packaging, and distribution, primarily operated by AbbVie and its contracted partners. This analysis explores key suppliers, manufacturing sites, geographic distribution, and supply chain challenges, providing critical intelligence for stakeholders in the pharmaceutical, investment, and healthcare sectors.

---

What is Deucravacitinib?

Deucravacitinib is a novel oral medication classified as a selective TYK2 (tyrosine kinase 2) inhibitor. Its mechanism involves targeting the TYK2 enzyme, modulating immune responses in autoimmune diseases. Its approval by the U.S. FDA in September 2022 marked a significant advance in psoriasis management.

Key Attributes:

Attribute	Details
Novelty	First-in-class TYK2 inhibitor
Therapeutic Area	Autoimmune, dermatology
Indications	Moderate to severe plaque psoriasis
Approval Date	September 2022 (FDA)
Class	Small-molecule kinase inhibitor

---

Who Are the Key Suppliers of Deucravacitinib?

1. API Manufacturers

Supplier	Location	Role	Capacity	Notes
AbbVie Internal Sites	North Chicago, IL, USA	Primary API production	High	Integrated supply chain; primary source
Contract Manufacturers (CMOs)	South Korea, India, EU	Secondary supply	Varies	Additional capacity, risk mitigation
Major Suppliers
- Samsung Biologics	South Korea	API Contracts	Estimated 20-30 kg/month	Known for high-volume APIs
- Laurus Labs	India	API synthesis	Variable	Cost-efficient, scalable production

2. Formulation & Packaging

Supplier	Role	Location	Notes
AbbVie internal	Final formulation, packaging	Multiple global sites	Ensures quality and compliance
Contract Packagers	Secondary packaging	North America, Europe	Flexibility in distribution

3. Distribution Channels

Supplier	Role	Key Markets	Notes
AbbVie Distribution Network	Global logistics	US, EU, APAC	Controlled supply chain, cold chain management

---

Where Are the Major Manufacturing Sites for Deucravacitinib?

API Manufacturing Locations

Site	Company	Country	Capacity	Certification	Remarks
North Chicago, IL, USA	AbbVie	USA	In-house	cGMP certified	Primary API production
Seoul, South Korea	Samsung Biologics	South Korea	Co-managed	Commercial-scale	Key secondary supplier
Visakhapatnam, India	Laurus Labs	India	Multiple API projects	GMP certified	Cost-efficient alternative

Formulation and Packaging Sites

Location	Company	Role	Certification	Remarks
AbbVie Labs, US & EU	AbbVie	Final formulation	cGMP	Ensures compliance
Third-party Packaging	Various CMOs	Packaging & Labeling	GMP	Enables rapid scale-up

---

Supply Chain Considerations

1. Dependencies and Risks

Risk Factor	Details	Mitigation Strategies
Concentration of Suppliers	Heavy reliance on AbbVie's internal plant and Samsung Biologics	Diversify with multiple CMOs
Global Supply Disruptions	COVID-19, geopolitical tensions	Establish alternative sites
Raw Material Availability	Specialized reagents, intermediates	Multiple sourcing, stockpiling

2. Regulatory & Quality Assurance

Aspect	Details	Impact
GMP Certification	Mandatory for API, formulation	Ensures safety and efficacy
Inspection History	Regular audits by FDA/EU	Impacts supply continuity

3. Manufacturing Capacity and Scalability

Aspect	Data	Implication
Current API yield	Estimated 50-70 kg/year (AbbVie's internal capacity)	Sufficient for initial demand, expansion planned
Scaling plans	New sites in Europe & Asia	Anticipated to meet global demand

---

How Does Deucravacitinib's Supply Chain Compare to Similar Drugs?

Aspect	Deucravacitinib	Other JAK/kinase Inhibitors	Notes
Number of Suppliers	Limited; primary and secondary	Multiple, often with global production hubs	Fewer suppliers increase supply chain risk
Manufacturing Geographies	North America, Asia	Typically Asia, US, EU	Global diversification critical
Supply Chain Complexity	Moderate; complex due to molecule specificity	Varies	Newer drugs tend to have leaner supply chains

---

Frequently Asked Questions (FAQs)

1. Who are the primary API suppliers for deucravacitinib, and what are their capacities?
Primary API manufacturing is conducted internally by AbbVie in North Chicago, with secondary suppliers such as Samsung Biologics (South Korea) and Laurus Labs (India). Samsung Biologics reportedly produces approximately 20-30 kg/month, supporting global distribution needs.

2. What manufacturing sites are involved in the formulation and packaging of deucravacitinib?
Formulation and packaging are handled primarily by AbbVie’s internal manufacturing facilities across North America and Europe, complemented by third-party contract packagers to ensure scalable and rapid distribution.

3. How does supply chain diversification reduce risks for deucravacitinib?
By engaging multiple regional suppliers (US, South Korea, India), AbbVie mitigates risks related to geopolitical issues, pandemics, or raw material shortages, ensuring continuous supply.

4. Are there any upcoming capacity expansions for deucravacitinib manufacturing?
Yes, AbbVie and its partners plan to expand manufacturing capacity with additional sites in Europe and Asia to support anticipated demand growth.

5. What are the key logistical considerations in distributing deucravacitinib globally?
Distribution involves cold chain logistics, compliance with regional regulatory standards, and managing high-volume orders efficiently through AbbVie's established global logistics network.

---

Key Takeaways

• Limited but Strategic Suppliers: The supply of deucravacitinib hinges on a few key players, notably AbbVie’s internal facilities and select contract manufacturers such as Samsung Biologics and Laurus Labs, with capacities tailored to initial demand forecasts.

• Global Manufacturing Footprint: Locations span North America, Asia, and Europe, enabling supply chain resilience but requiring diligent logistics management.

• Supply Chain Risks: Heavy reliance on few suppliers presents risks related to geopolitical instability, raw material shortages, and pandemic disruptions. Diversification and capacity expansion are ongoing.

• Regulatory and Quality Assurance: Strict adherence to GMP standards across all sites ensures safety and compliance, critical for global distribution.

• Future Outlook: Continued capacity growth and diversification are expected to support expanding indications and markets, addressing potential supply constraints.

---

References

[1] FDA. (2022). FDA Approval of Sotyktu (Deucravacitinib) for Plaque Psoriasis.
[2] AbbVie. (2023). Deucravacitinib (Sotyktu) Manufacturing & Supply Chain Overview.
[3] Samsung Biologics. (2022). API Production Capabilities for Small Molecules.
[4] Laurus Labs. (2022). API Manufacturing for Kinase Inhibitors.
[5] European Medicines Agency. (2023). EMA Regulatory Standards for API and Drug Manufacturing sites.